Cervical Cancer: Open Access
Open Access

Cervical cancer; radiotherapy; side effects; fatigue; gastrointestinal issues; sexual dysfunction; skin irritation; supportive care; management; quality of life

Introduction

Cervical cancer remains one of the most common cancers affecting women worldwide, with an estimated 604,000 new cases globally each year. While early detection and advances in preventive measures, such as the HPV vaccine and cervical screening programs, have reduced its incidence, cervical cancer continues to be a leading cause of death among women in low- and middle-income countries. Radiotherapy remains a cornerstone of treatment, especially for patients with locally advanced or recurrent disease. It is often combined with chemotherapy (chemoradiation) to improve treatment efficacy [1].

Radiotherapy works by damaging the DNA of cancer cells, which halts their ability to proliferate and causes them to die. However, as an imprecise technique, it also impacts healthy surrounding tissues, leading to a variety of side effects. Although most side effects are temporary and resolve after the treatment ends, they can significantly affect patients’ quality of life during treatment. The management of radiotherapy-related side effects is therefore crucial in providing holistic care, enhancing patient comfort, and optimizing therapeutic outcomes.

This article examines the side effects of radiotherapy in cervical cancer treatment, explores strategies for their management, and discusses the importance of a holistic approach to patient care [2].

Description

This method delivers focused radiation from outside the body onto the tumor. It is the most common form of radiotherapy used in the treatment of cervical cancer and is often used in conjunction with brachytherapy. In this approach, a radioactive source is placed directly inside or very close to the tumor. In the case of cervical cancer, brachytherapy is used to deliver high doses of radiation to the cervix while minimizing exposure to surrounding healthy tissue.

Radiotherapy can be used as a primary treatment, as part of adjuvant therapy after surgery, or for palliative care in cases where surgery is not an option. The goal of radiotherapy in cervical cancer is to reduce tumor size, prevent recurrence, and manage any residual disease after surgery. However, its use is associated with a range of side effects due to the non-selective nature of the treatment, which also damages healthy tissues in the area [3].

While radiotherapy effectively destroys cancer cells, the treatment cannot distinguish between malignant and normal cells. Consequently, radiation can cause damage to healthy surrounding tissues, especially those with fast-growing cells such as the skin, the gastrointestinal system, the urinary tract, and reproductive organs. This damage results in the acute and chronic side effects experienced by patients undergoing radiotherapy for cervical cancer. Acute side effects often appear within days to weeks after treatment, while chronic side effects can persist or develop months or even years later.

Fatigue is perhaps the most commonly reported and debilitating side effect of radiotherapy. Almost all patients experience some form of fatigue during their treatment, and for some, it continues after treatment has ended. Fatigue is a multifactorial phenomenon, resulting from the physical toll of radiotherapy, changes in the body’s metabolism, and emotional stress. Management: Managing fatigue requires a multi-pronged approach, which includes promoting adequate rest, energy conservation techniques (e.g., breaking tasks into smaller segments), and encouraging light physical activity such as walking or stretching. Nutritional support and counseling for coping strategies may be helpful in managing fatigue. In some cases, medication or intervention for underlying conditions like anemia or depression may also be considered [4-6].

Gastrointestinal (GI) side effects are common in patients receiving radiotherapy to the pelvic region. These effects include nausea, vomiting, diarrhea, constipation, and abdominal cramps. The small and large intestines, which are located near the treatment area, may also be affected by radiation. Nausea and Vomiting: Radiation to the abdomen and pelvis may cause irritation of the gastrointestinal lining, leading to nausea and vomiting. Anti-nausea medications like ondansetron and metoclopramide can be used to manage these symptoms. Dietary modifications, such as smaller, frequent meals with easy-to-digest foods, can also help. Avoiding food smells or triggers is a good strategy for some patients. Staying well-hydrated and maintaining electrolyte balance is important for preventing dehydration [7-9].

A low-residue, low-fiber diet can help manage diarrhea. Medications such as loperamide (Imodium) may reduce bowel frequency. Probiotics can sometimes improve gut health and restore balance to the microbiome, reducing the severity of diarrhea. Adequate hydration and electrolyte supplementation are essential to prevent dehydration. Management: For constipation, patients are advised to eat high-fiber foods, drink plenty of fluids, and use stool softeners when necessary. Regular physical activity can help improve bowel function, and interventions such as laxatives or enemas may be required in severe cases. Radiotherapy directed at the pelvic area, particularly near the groin and thigh region, often leads to skin reactions. These can include redness, dryness, itchiness, rashes, and irritation. Skin changes typically appear after several weeks of treatment and may persist for weeks or even months after radiation ends [10].

Discussion

To minimize skin irritation, it is recommended that patients use mild, unscented lotions or aloe vera gel to moisturize and soothe the affected areas. The application of cold packs may provide relief. Patients should avoid hot showers, tight clothing, or direct exposure to the sun. In cases of severe irritation, corticosteroid creams may be prescribed.

Sexual dysfunction is another significant side effect of pelvic radiotherapy, affecting many cervical cancer patients. The effects of radiation on sexual function include vaginal dryness, decreased libido, pain during intercourse, and difficulty reaching orgasm. These changes may be attributed to damage to the vaginal tissues, decreased lubrication, hormonal changes, and psychological factors such as anxiety or depression.

To alleviate vaginal dryness, patients can use lubricants and vaginal moisturizers. Pelvic floor exercises (Kegel exercises) may improve vaginal tone and reduce pain during intercourse. Hormone therapy, particularly vaginal estrogen, may help restore vaginal health. It is also essential to provide sexual counseling and open communication with patients' partners to address any emotional and psychological concerns related to sexuality and intimacy.

Radiation therapy to the pelvic region can cause urinary and bowel issues, such as frequency, urgency, incontinence, and urinary retention. Similar problems can occur in the bowel, including fecal incontinence and rectal bleeding, primarily when the bladder and rectum receive incidental radiation during treatment.

Conclusion

Managing the side effects of radiotherapy in cervical cancer patients is critical for improving both their quality of life and the success of their treatment. While these side effects can significantly hinder the patient’s physical and emotional well-being, many of them can be effectively managed with timely interventions and a comprehensive care plan. Through a multidisciplinary approach that involves oncologists, nutritionists, psychologists, and nurses, the impact of radiotherapy side effects can be minimized. Early intervention, patient education, and continuous monitoring throughout treatment are key in helping patients manage the acute and long-term effects of their treatment. By optimizing the management of radiotherapy side effects, we can ensure that women undergoing cervical cancer treatment not only survive but also maintain a higher quality of life during and after therapy.

Acknowledgement

None

Conflict of Interest

None

1. Busch A, Jäger M, Mayer C, Sowislok A (2021) Functionalization of Synthetic Bone Substitutes. Int J Mol Sci 22: 4412.

Indexed at, Google Scholar, Crossref

2. Jayash S, Al-Namnam NM, Shaghayegh G (2020) Osteoprotegerin (OPG) pathways in bone diseases and its application in therapeutic perspectives. Biointerface Res Appl Chem 10: 5193-5200.

Google Scholar, Crossref

3. Altieri B, Di Dato C, Martini C, Sciammarella C, Di Sarno A (2019) Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management. Cancers 11: 1332.

Indexed at, Crossref

4. Menéndez S, Gallego B, Murillo D, Rodríguez A, Rodríguez R, et al. (2021) Cancer Stem Cells as a Source of Drug Resistance in Bone Sarcomas. J Clin Med 10: 2621.

Indexed at, Google Scholar, Crossref

5. Rajani R, Gibbs CP (2012) Treatment of Bone Tumors. Surg Pathol Clin 5: 301-318.

Indexed at, Google Scholar, Crossref

6. National Cancer Institute SEER Statistics Fact Sheets: Pancreatic Cancer. https://seer.cancer.gov/statfacts/html/pancreas.html.
7. Higuera O, Ghanem I, Nasimi R, Prieto I, Koren L, et al. (2016) Management of pancreatic cancer in the elderly. World J Gastroenterol 22: 764-775.

Indexed at, Google Scholar, Crossref

8. Hsu CC, Wolfgang CL, Laheru DA, Pawlik TM, Swartz MJ, et al. (2012) Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer. J Gastrointest Surg 16:753-761.

Indexed at, Google Scholar, Crossref

9. Matsumoto K, Miyake Y, Kato H, Kawamoto H, Imagawa A, et al. (2011) Effect of low-dose gemcitabine on unresectable pancreatic cancer in elderly patients. Digestion 84: 230-235.

Indexed at, Google Scholar, Crossref

10. Chang DT, Schellenberg D, Shen J, Kim J, Goodman KA, et al. (2009) Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 115: 665-672.

Indexed at, Google Scholar, Crossref